Synteract cites global expansion as driver for HCR takeover

- Last updated on GMT

Related tags: Clinical trial, Europe

Synteract to buy HCR to expand reach
Synteract to buy HCR to expand reach
Synteract will add trial capacity in Europe, Israel and South America through the acquisition of Munich-based Harrison Clinical Research. (HCR).

The proposed acquisition – financial terms of which were not disclosed by the private equity-owned, San Francisco-headquartered contract research organisation (CRO) – will add HCR’s capabilities in early phase pharmacology and Phase II to IV services.

The deal – which is expected to complete in the first quarter – will create a combined company with a workforce of 800 employees in 16 countries under the leadership of Synteract CEO Wendel Barr.

Francisco Harrison – HCR founder and current chairman – will take a seat on the Synteract board and the Germany firm’s CEO Benedikt van Nieuwenhove will take change of operations in Europe.

Alex Earls, a spokesman for Synteract’s private-equity owners Gryphon Investors, explained that global expansion is the key motivated for the takeover.

The acquisition provides Synteract with a strong geographic presence in Western and Eastern Europe and an emerging presence in South America.

Importantly, this acquisition will allow Synteract to more effectively meet the global trial needs of its customer base and brings significant adaptive trial, medical device and nutraceutical expertise to the combined company.”

Synteract’s only current European operation is its office in Prague in the Czech Republic that it opened in 2009​ in a bid to increase its access to treatment naïve clinical trial participants.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars